Prosecution Insights
Last updated: November 04, 2026
Application No. 18/908,101

TOPICAL GLYCOPYRROLATE FORMULATIONS

Final Rejection §102§103§DOUBLEPATENT
Filed
Oct 07, 2024
Priority
Oct 18, 2007 — provisional 60/960,887 +9 more
Examiner
ROGERS, JAMES WILLIAM
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Rose U LLC
OA Round
1 (Final)
46%
Grant Probability
Moderate
2-3
OA Rounds
1y 9m
Est. Remaining
69%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allowance Rate
420 granted / 907 resolved
-13.7% vs TC avg
Strong +23% interview lift
Without
With
+22.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
49 currently pending
Career history
966
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
42.5%
+2.5% vs TC avg
§102
22.2%
-17.8% vs TC avg
§112
23.9%
-16.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 907 resolved cases

Office Action

§102 §103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of pre-AIA 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States. Claim(s) 36-38 is/are rejected under pre-AIA 35 U.S.C. 102b as being anticipated by Wassenaar (US 7,060,289), cited parent application 18/142,409. Wassenaar discloses topical glycopyrrolate pads with 0.25-6 wt% glycopyrrolate which were wiped unto areas of excessive sweeting to treat hyperhidrosis, the pads were made by moistening the pads and sealing a container (considered to read on sealable pouch). See entire disclosure, especially abstract, col 1 lines 5-17, col 2 lines 14-43, col 3 lines 2-41, col 7 line 50-col 8 line 3 and claim 1. It is noted by the examiner that applicants define pouch in the specification at [0049] as “As used herein, the term “pouch” refers to a structure that defines a discrete space into which a wipe/pad can be inserted”. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under pre-AIA 35 U.S.C. 103(a) are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims under pre-AIA 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of pre-AIA 35 U.S.C. 103(c) and potential pre-AIA 35 U.S.C. 102(e), (f) or (g) prior art under pre-AIA 35 U.S.C. 103(a). Claims 36-38 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wassenaar (US 7,060,289) in view of (Kuy US 4355020, cited parent application 18/142,409). As noted above Wassenaar teaches pads comprising from about 0.25% to about 6% of a glycopyrrolate compound. While the examiner believes the container of Wassenaar reads on the broadly claimed pouch it would also be obvious when the disclosure of Kuy is considered. Kuy teaches an individually packaged wipe comprising a composition to treat hyperhidrosis, wherein said wipe is contained within a pouch resistant to leakage for the treatment of hyperhidrosis. See entire disclosure, especially abstract, col. 9, lines 35-41, example 19, col. 10, line 18. It would have been obvious to a person skilled in the art to combine the individually packaged wipe taught by Kuy and apply it to the wipe taught by Wassenaar in order to effectively provide a product protected for reduction of the possibility of evaporation or leakage of the composition contained in the wipe. Thus the claimed invention would have been prima facie obvious since all the claimed elements were known in the prior art and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions and the combination would have yielded predictable results to one of ordinary skill in the art at the time of the invention. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claim 36-38 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 8,618,160. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims represent a sub-genus of instant generic claims, thereby rendering instant generic claims not patentably distinct. That is the patent requires more specific components including buffering agent and alcohol, however the instant claims are generic and include within their scope all that the patented claims recite, rendering them patentably indistinct. Claim 36-38 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-28 of U.S. Patent No. 8,859,610. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims represent a sub-genus of instant generic claims, thereby rendering instant generic claims not patentably distinct. That is the patent requires more specific glycopyrrolate compounds, however the instant claims are generic and include within their scope all that the patented claims recite, rendering them patentably indistinct. Claim 36-38 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-31 of US 9,006,462 B2. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims represent a sub-genus of instant generic claims, thereby rendering instant generic claims not patentably distinct. That is the patent requires more specific components, however the instant claims are generic and include within their scope all that the patented claims recite, rendering them patentably indistinct. Claim 36-38 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-29 of U.S. Patent No. 9,744,105. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims represent a sub-genus of instant generic claims, thereby rendering instant generic claims not patentably distinct. That is the patent requires more specific components including buffering agent and alcohol, however the instant claims are generic and include within their scope all that the patented claims recite, rendering them patentably indistinct. Claim 36-38 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-31 of US 10,004,717 B2. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims represent a sub-genus of instant generic claims, thereby rendering instant generic claims not patentably distinct. That is the patent requires more specific components, however the instant claims are generic and include within their scope all that the patented claims recite, rendering them patentably indistinct. Claim 36-38 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 10,052,267. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims represent a sub-genus of instant generic claims, thereby rendering instant generic claims not patentably distinct. That is the patent requires more specific components including buffering agent and alcohol, however the instant claims are generic and include within their scope all that the patented claims recite, rendering them patentably indistinct. Claim 36-38 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-18 of U.S. Patent No. 11,071,694. Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims represent a sub-genus of instant generic claims, thereby rendering instant generic claims not patentably distinct. That is the patent requires more specific components including buffering agent and alcohol, however the instant claims are generic and include within their scope all that the patented claims recite, rendering them patentably indistinct. Conclusion This is a continuation of applicant's earlier Application No. 18/666,553, now abandoned, which itself is a continuation of 18/142,409, now abandoned. All claims are identical to, patentably indistinct from, or have unity of invention with the invention claimed in the earlier application (that is, restriction (including lack of unity) would not be proper) and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the earlier application. Accordingly, THIS ACTION IS MADE FINAL even though it is a first action in this case. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAMES W ROGERS whose telephone number is (571)272-7838. The examiner can normally be reached 9:30-6:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JAMES W ROGERS/Primary Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Oct 07, 2024
Application Filed
Oct 27, 2026
Final Rejection mailed — §102, §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779085
RADIOPAQUE POLYMERS
3y 3m to grant Granted Nov 03, 2026
Patent 12779054
LANTHANIDE COMPLEX FORMULATIONS
2y 3m to grant Granted Nov 03, 2026
Patent 12759047
Metal-based core nanoparticles, synthesis and use
4y 3m to grant Granted Oct 13, 2026
Patent 12758636
POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS
3y 6m to grant Granted Oct 13, 2026
Patent 12758658
DOUBLE-COMPONENT GASTRIC ULTRASOUND EXAMINATION AIDED DEVELOPER AND PREPARATION METHOD THEREFOR
2y 10m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
46%
Grant Probability
69%
With Interview (+22.6%)
3y 10m (~1y 9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 907 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month